A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MOBILE
  • Sponsors Biogen Idec
  • Most Recent Events

    • 23 Jun 2015 Patient-reported outcome results presented at the 1st Congress of the European Academy of Neurology.
    • 12 Nov 2014 Primary endpoint (Change in subjective impression of well-being measured by Euro Quality of Life-5D (EQ-5D)) has been met according to results presented at the 17th Annual EISPOR.
    • 12 Nov 2014 Results presented at the 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top